electroCore’s TAC‑STIM was named a national semifinalist in the National Safety Council’s Work to Zero Safety Innovation Challenge, a competition that rewards technologies designed to reduce workplace fatigue, a leading safety risk that can impair judgment and increase accident likelihood. The device, developed in partnership with the U.S. Air Force Research Laboratory, delivers non‑invasive vagus nerve stimulation to lower fatigue and improve attention in high‑demand environments. The semifinalists will present at the NSC Safety Summit on May 7‑8, 2026, giving TAC‑STIM exposure to a broad audience of safety professionals and potential customers.
The recognition signals that TAC‑STIM’s technology is gaining traction beyond the VA and wellness markets. It is already deployed by U.S. Air Force, Army, and Navy commands, and the award could accelerate adoption by additional military and commercial customers, expanding electroCore’s human‑performance portfolio. The award also positions the company to tap into the Work to Zero Pilot Grant Program, which supports real‑world implementation of promising safety technologies.
Joshua Lev, interim president and chief financial officer of electroCore, said, “We are honored that TAC‑STIM has been recognized by the National Safety Council as an innovative solution to decrease workplace fatigue. Fatigue decreases performance and safety across a wide range of industries, and TAC‑STIM was developed to provide a practical, scalable tool to help individuals maintain focus, make better decisions, and perform at their best when it matters most.”
Dr. Matt Law, director of Work to Zero at the National Safety Council, added, “Fatigue is a serious and underrecognized risk factor across many industries. When workers are exhausted, the risk of life‑altering or fatal incidents rises.”
ElectroCore reported full‑year 2025 revenue of $32.0 million, a 27% increase over 2024, and is targeting 30% annual revenue growth for 2026. As of December 31, 2025, the company held $11.6 million in cash and posted a net loss of $13.966 million for the trailing twelve months. The semifinalist designation could help the company convert its growing revenue base into broader market penetration and potentially improve its financial trajectory by attracting new customers and grant funding.
The award underscores continued interest in electroCore’s neuromodulation platform and suggests opportunities for further partnerships, research collaborations, and product development. By validating TAC‑STIM’s effectiveness in reducing fatigue, the recognition enhances the company’s credibility and may accelerate its expansion into new safety‑critical sectors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.